Insulet's Omnipod System Faces Class I Recall by FDA
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: seekingalpha
- FDA Recall Classification: Insulet's Omnipod insulin pump system has been classified as a Class I recall by the FDA due to potential tubing tears, representing the most serious recall type and posing risks of insulin under-delivery, which could jeopardize patient health.
- Affected Products: The recall affects the Omnipod 5, Omnipod DASH, and Omnipod Eros models, with Insulet indicating that the cannula may have small tears above the skin, leading to insulin leakage instead of proper delivery into the body.
- Safety Incident Reports: As of May 20, Insulet has reported 24 serious injuries related to this issue, although there have been no fatalities, highlighting the critical importance of product safety and the need for effective risk management.
- Market Response: Despite the recall pressures, Insulet's stock has shown resilience with a buy rating from Deutsche Bank, indicating investor confidence in the company's ability to recover and address the safety concerns effectively.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PODD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PODD
Wall Street analysts forecast PODD stock price to rise
19 Analyst Rating
18 Buy
1 Hold
0 Sell
Strong Buy
Current: 159.790
Low
316.00
Averages
375.83
High
450.00
Current: 159.790
Low
316.00
Averages
375.83
High
450.00
About PODD
Insulet Corporation is a medical device company. It is primarily engaged in the development, manufacture and sale of its continuous insulin delivery systems for people with insulin-dependent diabetes. The Omnipod System includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5), the Omnipod DASH Insulin Management System, and the Omnipod Insulin Management System. The Omnipod platform offers continuous insulin delivery that provides various benefits of insulin pump therapy in a way without the need for external tubing required with conventional pumps. The small, lightweight, self-adhesive disposable tubeless Omnipod device (Pod), can be worn in multiple locations, including the abdomen, hip, back of upper arm, upper thigh, or lower back, and delivers insulin into the body through a small flexible tube. It also produces pods for Amgen for use in the Neulasta Onpro kit, a delivery system for Amgen’s Neulasta to help reduce the risk of infection after intense chemotherapy.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Insulet's Omnipod System Faces Class I Recall by FDA
- FDA Recall Classification: Insulet's Omnipod insulin pump system has been classified as a Class I recall by the FDA due to potential tubing tears, representing the most serious recall type and posing risks of insulin under-delivery, which could jeopardize patient health.
- Affected Products: The recall affects the Omnipod 5, Omnipod DASH, and Omnipod Eros models, with Insulet indicating that the cannula may have small tears above the skin, leading to insulin leakage instead of proper delivery into the body.
- Safety Incident Reports: As of May 20, Insulet has reported 24 serious injuries related to this issue, although there have been no fatalities, highlighting the critical importance of product safety and the need for effective risk management.
- Market Response: Despite the recall pressures, Insulet's stock has shown resilience with a buy rating from Deutsche Bank, indicating investor confidence in the company's ability to recover and address the safety concerns effectively.
See More
Wall Street's Favorite Long-Term Investment Stocks
- Chewy's Sales Struggles: Chewy (CHWY) has experienced only 7.1% annual sales growth over the past three years, significantly lagging behind peers, with projected sales growth of just 6.8% for the next 12 months indicating weak demand that could hinder market performance.
- Alarm.com Performance Stagnation: Alarm.com (ALRM) has seen an average billings growth of only 8.4% over the past year, with estimated sales growth dropping to 3.6% for the next 12 months, suggesting a slowdown in demand, while its static operating margin reflects efficiency issues.
- Insulet's Positive Market Outlook: Insulet (PODD) is poised for growth with its tubeless
See More
Major Rating Changes on Wall Street
- IBM Upgrade: JPMorgan upgraded IBM from Neutral to Overweight, citing a deeper analysis of its software business that suggests significant performance acceleration in 2H'26, thereby enhancing market confidence in the company's growth trajectory.
- Qiagen Upgrade: Morgan Stanley upgraded Qiagen from Equal Weight to Overweight, noting that AI-driven growth improvements and the clearing of competitive risks are expected to positively impact the life sciences sector.
- Smurfit Westrock Initiation: Deutsche Bank initiated coverage of Smurfit Westrock with a Buy rating and a $57 price target, emphasizing its high-margin operations and strong market position as catalysts for value creation in the packaging industry.
- Target Upgrade: Wolfe upgraded Target from Peer Perform to Outperform, stating that now is the optimal time to buy, as the company is poised for significant improvements driven by store resets and a new leadership team shaking up the status quo.
See More
Insulet Reports Promising Clinical Trial Results for Next-Gen Insulin Delivery Systems
- Clinical Trial Results: Insulet presented promising clinical trial results for its next-generation tubeless Automated Insulin Delivery systems at the American Diabetes Association's 86th Scientific Sessions, with the STRIVE trial demonstrating strong glycemic control and the ability to deliver up to 50% more automated insulin, significantly reducing the need for manual boluses across various age groups and diabetes types.
- Closed-Loop System Study: The company also shared findings from the EVOLUTION 3 feasibility study, which focused on a fully closed-loop system for type 2 diabetes, designed to automatically adjust insulin levels without requiring manual user settings, thereby simplifying clinical workflows and removing traditional barriers to care.
- Alignment with Innovation Strategy: These technological advancements align with Insulet's broader innovation strategy that prioritizes technology requiring less daily effort from users while improving health outcomes, indicating the company's commitment to making diabetes management more automated and accessible.
- Market Potential Outlook: While Insulet is recognized as a stock with investment potential, analysts note that certain AI stocks may offer greater upside potential and lower downside risk, reflecting the market's diverse focus on different technology sectors and investment opportunities.
See More
Insulet's Omnipod 6 Shows Strong Clinical Outcomes in Diabetes Management
- STRIVE Trial Results: The STRIVE pivotal trial involved 132 participants with HbA1c levels of 6.9% for type 1 and 7.3% for type 2 diabetes, demonstrating significant glycemic control improvements with Omnipod 6, particularly showing 54% of time in the 70-140 mg/dL range for type 1 diabetes, a 7-point increase over Omnipod 5, indicating its potential in diabetes management.
- EVOLUTION 3 Study Findings: The EVOLUTION 3 study revealed that the fully closed-loop system for type 2 diabetes maintained 64% time in range while reducing daily insulin from 86 units to 58 units without weight gain, showcasing its effectiveness in enhancing patient quality of life.
- Enhanced User Experience: In the EVOLUTION 3 study, 86% of participants reported satisfaction or high satisfaction with the fully closed-loop system, indicating that the technology not only achieved clinical success but also significantly reduced the burden of diabetes management, facilitating clinical adoption.
- Future Research Directions: Insulet plans to further evaluate Omnipod 6 in the upcoming STRIVE 2 study among patients who bolus fewer than four times daily and do not meet HbA1c clinical targets, demonstrating the company's commitment to ongoing innovation and improved diabetes management.
See More
Quantum Stocks Decline While Consumer Staples Rise
- Quantum Stocks Struggle: Quantinuum's debut on Nasdaq was lackluster, closing flat and subsequently dropping over 8% on Friday, falling below its IPO price of $60 per share, indicating market caution towards the quantum computing sector which may impact future funding and investor confidence.
- Consumer Staples Surge: Amid Friday's market sell-off, the consumer staples sector rose 2%, with companies like Colgate-Palmolive, Coca-Cola, and Procter & Gamble gaining over 3%, reflecting investor preference for defensive stocks, which could lead to a shift in capital towards these stable industries.
- Strong Performance in Medical Devices: Cooper Companies reported second-quarter adjusted earnings of $1.21 per share, exceeding the $1.10 consensus estimate, with revenue of $1.08 billion surpassing the $1.05 billion forecast, showcasing robust performance in the medical device sector that may attract more investor interest.
- Software Stocks Outlook Weakens: Docusign's outlook failed to impress, with shares slipping 6% as it projected second-quarter revenue between $865 million and $869 million, slightly below consensus, potentially affecting its future market performance and investor confidence.
See More
Insulet's Omnipod System Faces Class I Recall by FDA
- FDA Recall Classification: Insulet's Omnipod insulin pump system has been classified as a Class I recall by the FDA due to potential tubing tears, representing the most serious recall type and posing risks of insulin under-delivery, which could jeopardize patient health.
- Affected Products: The recall affects the Omnipod 5, Omnipod DASH, and Omnipod Eros models, with Insulet indicating that the cannula may have small tears above the skin, leading to insulin leakage instead of proper delivery into the body.
- Safety Incident Reports: As of May 20, Insulet has reported 24 serious injuries related to this issue, although there have been no fatalities, highlighting the critical importance of product safety and the need for effective risk management.
- Market Response: Despite the recall pressures, Insulet's stock has shown resilience with a buy rating from Deutsche Bank, indicating investor confidence in the company's ability to recover and address the safety concerns effectively.
See More
Wall Street's Favorite Long-Term Investment Stocks
- Chewy's Sales Struggles: Chewy (CHWY) has experienced only 7.1% annual sales growth over the past three years, significantly lagging behind peers, with projected sales growth of just 6.8% for the next 12 months indicating weak demand that could hinder market performance.
- Alarm.com Performance Stagnation: Alarm.com (ALRM) has seen an average billings growth of only 8.4% over the past year, with estimated sales growth dropping to 3.6% for the next 12 months, suggesting a slowdown in demand, while its static operating margin reflects efficiency issues.
- Insulet's Positive Market Outlook: Insulet (PODD) is poised for growth with its tubeless
See More
Major Rating Changes on Wall Street
- IBM Upgrade: JPMorgan upgraded IBM from Neutral to Overweight, citing a deeper analysis of its software business that suggests significant performance acceleration in 2H'26, thereby enhancing market confidence in the company's growth trajectory.
- Qiagen Upgrade: Morgan Stanley upgraded Qiagen from Equal Weight to Overweight, noting that AI-driven growth improvements and the clearing of competitive risks are expected to positively impact the life sciences sector.
- Smurfit Westrock Initiation: Deutsche Bank initiated coverage of Smurfit Westrock with a Buy rating and a $57 price target, emphasizing its high-margin operations and strong market position as catalysts for value creation in the packaging industry.
- Target Upgrade: Wolfe upgraded Target from Peer Perform to Outperform, stating that now is the optimal time to buy, as the company is poised for significant improvements driven by store resets and a new leadership team shaking up the status quo.
See More
Insulet Reports Promising Clinical Trial Results for Next-Gen Insulin Delivery Systems
- Clinical Trial Results: Insulet presented promising clinical trial results for its next-generation tubeless Automated Insulin Delivery systems at the American Diabetes Association's 86th Scientific Sessions, with the STRIVE trial demonstrating strong glycemic control and the ability to deliver up to 50% more automated insulin, significantly reducing the need for manual boluses across various age groups and diabetes types.
- Closed-Loop System Study: The company also shared findings from the EVOLUTION 3 feasibility study, which focused on a fully closed-loop system for type 2 diabetes, designed to automatically adjust insulin levels without requiring manual user settings, thereby simplifying clinical workflows and removing traditional barriers to care.
- Alignment with Innovation Strategy: These technological advancements align with Insulet's broader innovation strategy that prioritizes technology requiring less daily effort from users while improving health outcomes, indicating the company's commitment to making diabetes management more automated and accessible.
- Market Potential Outlook: While Insulet is recognized as a stock with investment potential, analysts note that certain AI stocks may offer greater upside potential and lower downside risk, reflecting the market's diverse focus on different technology sectors and investment opportunities.
See More
Insulet's Omnipod 6 Shows Strong Clinical Outcomes in Diabetes Management
- STRIVE Trial Results: The STRIVE pivotal trial involved 132 participants with HbA1c levels of 6.9% for type 1 and 7.3% for type 2 diabetes, demonstrating significant glycemic control improvements with Omnipod 6, particularly showing 54% of time in the 70-140 mg/dL range for type 1 diabetes, a 7-point increase over Omnipod 5, indicating its potential in diabetes management.
- EVOLUTION 3 Study Findings: The EVOLUTION 3 study revealed that the fully closed-loop system for type 2 diabetes maintained 64% time in range while reducing daily insulin from 86 units to 58 units without weight gain, showcasing its effectiveness in enhancing patient quality of life.
- Enhanced User Experience: In the EVOLUTION 3 study, 86% of participants reported satisfaction or high satisfaction with the fully closed-loop system, indicating that the technology not only achieved clinical success but also significantly reduced the burden of diabetes management, facilitating clinical adoption.
- Future Research Directions: Insulet plans to further evaluate Omnipod 6 in the upcoming STRIVE 2 study among patients who bolus fewer than four times daily and do not meet HbA1c clinical targets, demonstrating the company's commitment to ongoing innovation and improved diabetes management.
See More
Quantum Stocks Decline While Consumer Staples Rise
- Quantum Stocks Struggle: Quantinuum's debut on Nasdaq was lackluster, closing flat and subsequently dropping over 8% on Friday, falling below its IPO price of $60 per share, indicating market caution towards the quantum computing sector which may impact future funding and investor confidence.
- Consumer Staples Surge: Amid Friday's market sell-off, the consumer staples sector rose 2%, with companies like Colgate-Palmolive, Coca-Cola, and Procter & Gamble gaining over 3%, reflecting investor preference for defensive stocks, which could lead to a shift in capital towards these stable industries.
- Strong Performance in Medical Devices: Cooper Companies reported second-quarter adjusted earnings of $1.21 per share, exceeding the $1.10 consensus estimate, with revenue of $1.08 billion surpassing the $1.05 billion forecast, showcasing robust performance in the medical device sector that may attract more investor interest.
- Software Stocks Outlook Weakens: Docusign's outlook failed to impress, with shares slipping 6% as it projected second-quarter revenue between $865 million and $869 million, slightly below consensus, potentially affecting its future market performance and investor confidence.
See More
